345 related articles for article (PubMed ID: 22892872)
1. Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.
Aoyama Y; Kaibara A; Takada A; Nishimura T; Katashima M; Sawamoto T
Invest New Drugs; 2013 Apr; 31(2):443-51. PubMed ID: 22892872
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.
Aoyama Y; Nishimura T; Sawamoto T; Satoh T; Katashima M; Nakagawa K
Cancer Chemother Pharmacol; 2012 Sep; 70(3):373-80. PubMed ID: 22806304
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Kelly RJ; Thomas A; Rajan A; Chun G; Lopez-Chavez A; Szabo E; Spencer S; Carter CA; Guha U; Khozin S; Poondru S; Van Sant C; Keating A; Steinberg SM; Figg W; Giaccone G
Ann Oncol; 2013 Oct; 24(10):2601-2606. PubMed ID: 23857959
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
[TBL] [Abstract][Full Text] [Related]
6. A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.
Kudchadkar R; Ernst S; Chmielowski B; Redman BG; Steinberg J; Keating A; Jie F; Chen C; Gonzalez R; Weber J
Cancer Med; 2015 May; 4(5):643-50. PubMed ID: 25533314
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.
Satoh T; Okamoto I; Miyazaki M; Morinaga R; Tsuya A; Hasegawa Y; Terashima M; Ueda S; Fukuoka M; Ariyoshi Y; Saito T; Masuda N; Watanabe H; Taguchi T; Kakihara T; Aoyama Y; Hashimoto Y; Nakagawa K
Clin Cancer Res; 2009 Jun; 15(11):3872-80. PubMed ID: 19470738
[TBL] [Abstract][Full Text] [Related]
8. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
[TBL] [Abstract][Full Text] [Related]
9. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.
Lewis KD; Samlowski W; Ward J; Catlett J; Cranmer L; Kirkwood J; Lawson D; Whitman E; Gonzalez R
Invest New Drugs; 2011 Feb; 29(1):161-6. PubMed ID: 19830389
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
Papadopoulos KP; Lopez-Jimenez J; Smith SE; Steinberg J; Keating A; Sasse C; Jie F; Thyss A
Leuk Lymphoma; 2016 Aug; 57(8):1848-55. PubMed ID: 26857688
[TBL] [Abstract][Full Text] [Related]
11. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
[TBL] [Abstract][Full Text] [Related]
12. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
[TBL] [Abstract][Full Text] [Related]
13. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
Shimizu T; Nishio K; Sakai K; Okamoto I; Okamoto K; Takeda M; Morishita M; Nakagawa K
Cancer Chemother Pharmacol; 2020 Aug; 86(2):211-219. PubMed ID: 32638093
[TBL] [Abstract][Full Text] [Related]
14. Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.
Murakami Y; Matsuya T; Kita A; Yamanaka K; Noda A; Mitsuoka K; Nakahara T; Miyoshi S; Nishimura S
Nucl Med Biol; 2013 Feb; 40(2):221-6. PubMed ID: 23141550
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
Giaccone G; Zatloukal P; Roubec J; Floor K; Musil J; Kuta M; van Klaveren RJ; Chaudhary S; Gunther A; Shamsili S
J Clin Oncol; 2009 Sep; 27(27):4481-6. PubMed ID: 19687333
[TBL] [Abstract][Full Text] [Related]
17. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.
Tolcher AW; Quinn DI; Ferrari A; Ahmann F; Giaccone G; Drake T; Keating A; de Bono JS
Ann Oncol; 2012 Apr; 23(4):968-73. PubMed ID: 21859898
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
20. Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-Hodgkin lymphoma.
Aoyama Y; Katashima M; Sawamoto T
Biopharm Drug Dispos; 2013 Mar; 34(2):137-40. PubMed ID: 23138529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]